RE:Financing? Hey AP
Could be ... noting that, based on the latest 6 months cash burn), they likely have enough $ * to get to December ( which technically gets them close to or past Trial completion date - but perhaps not to Top Line data release ( Feb?) or final FDA decision ( spring 2025?)
Sure would help if there was even a modicum of promotion. Wouldn't take much to capture market attention, especially for a revolutionary Sepsis treatment that is on the eve of FDA approval.
But of course that would necessitate bringing in new retail investors - something that Spectral has NEVER shown any interest in doing.
MM
* about $9 M as of July including June 30 cash reported of $7.5 plus $1M USD from special financing in July